Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at treatment for acute myeloid leukaemia and high risk myelodysplastic syndrome - intensive treatment group (AML16)
This trial was looking at intensive treatment for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). MDS is called high risk if more than 10% of your
The trial was supported by Cancer Research UK. It was focusing on those who are over 60 years of age, but a small number of younger people did take part.
There were 2 parts to the AML 16 trial - intensive treatment and non intensive treatment. This summary is about intensive treatment. The summary about non intensive treatment is entered separately on our trials database.
The main aim of the intensive treatment part of the trial was to look at a number of different drugs to find out which was best at stopping AML coming back and caused the fewest side effects.
More about this trial
Treatment to get rid of AML or MDS is called induction therapy. The people taking part in this trial had 2 or more of the following drugs
- Gemtuzumab ozogamicin (also called Mylotarg or GO)
The aims of the trial were to
- Find out if having GO with chemotherapy was beneficial
- Compare the combination of daunorubicin and cytarabine (DA) chemotherapy, with a combination of daunorubicin and clofarabine
- Compare DA chemotherapy with DA plus etoposide (ADE)
- Find out whether a subgroup of patients benefited from ATRA therapy, and whether this depended on the type of chemotherapy they had (DA or ADE)
Other aims of the trial were to
Summary of results
The researchers have produced results from the parts of the trial that looked at
- Gemtuzumab ozogamicin (also known as Mylotarg or GO)
- The combination of daunorubicin and cytarabine compared to the combination of daunorubicin and clofarabine
- Adding a 3rd cycle of chemotherapy
GO is a monoclonal antibody that is attached to a chemotherapy drug called calicheamicin (pronounced cal-ick-ee-my-sin).The trial team found that adding GO to induction chemotherapy reduced the risk of leukaemia coming back.
The people taking part in the trial were put into treatment groups at random. Neither the person taking part nor their doctor could decide which group they were in. This is called randomisation. Between 2006 and 2010, the trial recruited 1,115 people into 4 treatment groups. They had 1 of the following drug combinations
- Daunorubicin and cytarabine
- Daunorubcin, cytarabine and a single dose of GO
- Daunorubicin and clofarabine
- Daunorubcin, clofarabine and a single dose of GO
The people taking part had not had any other treatment for AML or MDS and their average age was 67. Everybody had 2 cycles of chemotherapy. If their AML or MDS had completely disappeared after the 1st or 2nd cycle (they were in
After the last cycle of chemotherapy, some people were able to have a stem cell transplant. The people who weren’t able to have a transplant could be randomised once more to have maintenance treatment with the drug azacitidine or to have no further treatment.
In 2012, the trial team published results showing the effect of having gemtuzumab ozogamicin (GO).
Of the people who went into remission, AML or MDS came back in fewer people who had GO with chemotherapy than people who had chemotherapy alone.
The researchers followed the progress of the people taking part and found that after 2 years
- 35% of people who had GO with chemotherapy were still alive
- 29% of people who had chemotherapy alone were still alive
The trial team concluded that people who had GO with chemotherapy had a lower risk of leukaemia or MDS coming back and lived longer than people who had chemotherapy alone.
The researchers have also published results form the comparison of different chemotherapy drugs and number of treatment cycles. When they compared the combination of daunorubicin and cytarabine with the combination of daunorubicin and clofarabine, they found there wasn't any difference in the response rate or in the average length of time people lived for.
They also found that there was no significant benefit to people having a 3rd cycle of chemotherapy overall, but further work is needed to find out if some subgroups of patients might benefit.
The researchers need to follow up the patients for longer before analysing the results from other drugs looked at in the trial.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Alan Burnett
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/06/026.